4 news items
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential benefits of APHEXDA, the execution
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
). Secondary objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential benefits
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
and intentions regarding, among other things, the potential benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives
- Prev
- 1
- Next